Adiponectin in patients with metabolic syndrome and diseases of the liver, bile ducts and pancreas
- 1 December 2017
- journal article
- review article
- Published by Solen s.r.o. in Vnitrni Lekarstvi
- Vol. 63 (12), 945-948
- https://doi.org/10.36290/vnl.2017.172
Abstract
Epidemiological data show that the metabolic syndrome can be diagnosed in up to 30 % of the population. Regarding 5 components of the metabolic syndrome, three of them, in case of positivity (visceral obesity, arterial hypertension, hypertriglyceridemia, changes of HDL-cholesterol levels and type 2 diabetes mellitus), are pathogenic factors which are the most frequently related to cardiovascular diseases, but currently they are also the focus of interest for gastroenterologists. The relationship between non-alcoholic hepatic steatosis, including non-alcoholic steatohepatitis, has been described. Less is known so far about the relation to the pancreas disease, particularly with respect to the status referred to as non-alcoholic fatty pancreas disease. The hormone selectively produced by adipose tissue is adiponectin. This protein is studied as a possible biomarker in people with metabolic syndrome, including obesity. Besides that, there is a question studied whether adiponectin can also play a significant role in the pathogenesis of diseases associated with fat building up in parenchymatous organs. Finding a reliable biomarker for patients with metabolic syndrome or diseases of the liver, biliary system and pancreas in relation to metabolic syndrome, presents a big challenge. And adiponectin is one of the promising biomarkers.Key words: adiponectin - biliary disease - metabolic syndrome - pancreatic steatosis - steatohepatitis.Keywords
This publication has 26 references indexed in Scilit:
- Visceral adiposity as a target for the management of the metabolic syndromeAnnals of Medicine, 2011
- Molecular mechanisms of signal transduction via adiponectin and adiponectin receptorsBiological Chemistry, 2010
- Pancreatic steatosis in humans: cause or marker of lipotoxicity?Current Opinion in Clinical Nutrition and Metabolic Care, 2010
- The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver diseaseDiabetes, Obesity and Metabolism, 2010
- Low Serum Adiponectin Levels Are Associated With Systemic Organ Failure in Acute PancreatitisPancreas, 2009
- Harmonizing the Metabolic SyndromeJournal of the American College of Cardiology, 2009
- Adipocytokines and liver diseaseThe Esophagus, 2008
- Adiponectin plays a protective role in caerulein-induced acute pancreatitis in mice fed a high-fat dietGut, 2008
- Serum Adiponectin and Leptin Concentrations in Patients With Chronic Pancreatitis of Alcoholic and Nonalcoholic OriginPancreas, 2008
- Leptin and Adiponectin Levels in Acute PancreatitisPancreas, 2006